

Abstract

Tumour vaccine and process for the preparation thereof.
5 The tumour vaccine contains tumour cells at least some
of which contain at least one MHC-I-haplotype of the
patient on the cell surface, and which are charged with
one or more peptides binding to the MHC-I molecule in
such a way that the tumour cells are recognised as
10 foreign by the patient's immune system in context with
the peptides and trigger a cellular immune response.
The charging is carried out in the presence of a
polycation such as polylysine.